1. Home
  2. VHI vs PHVS Comparison

VHI vs PHVS Comparison

Compare VHI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VHI

Valhi Inc.

HOLD

Current Price

$12.52

Market Cap

370.5M

Sector

Industrials

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$24.99

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHI
PHVS
Founded
1932
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
370.5M
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VHI
PHVS
Price
$12.52
$24.99
Analyst Decision
Sell
Buy
Analyst Count
1
9
Target Price
$12.00
$39.44
AVG Volume (30 Days)
26.0K
271.8K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
2.46%
N/A
EPS Growth
N/A
N/A
EPS
0.65
N/A
Revenue
$2,063,400,000.00
N/A
Revenue This Year
$22.20
N/A
Revenue Next Year
$7.66
N/A
P/E Ratio
$20.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.44
$11.51
52 Week High
$25.25
$29.80

Technical Indicators

Market Signals
Indicator
VHI
PHVS
Relative Strength Index (RSI) 53.94 48.84
Support Level $11.44 $23.62
Resistance Level $13.11 $28.43
Average True Range (ATR) 0.48 1.57
MACD 0.14 -0.15
Stochastic Oscillator 76.65 29.52

Price Performance

Historical Comparison
VHI
PHVS

About VHI Valhi Inc.

Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: